FibroGen (FGEN) Misses Q2 EPS by 100c

FibroGen (NASDAQ: FGEN) reported Q2 EPS of ($1.45), $1.00 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $24.4 million versus the consensus estimate of $71.38 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.

You May Also Be Interested In

• Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
• MetaVia Inc. (MTVA) Tops Q2 EPS by 73c
• Alta Mesa Resources (AMR) Misses Q2 EPS by 128c